Revenue
2014
Protara Therapeutics, Inc. (TARA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | — | $2.9M | — | — |
| Research & development | $42.6M | $31.7M | $25.0M | $16.8M | $21.1M | $12.0M | $3.9M | $11.8M | $21.7M | $18.9M | $12.4M | $6.4M | $4.0M | $5.9M |
| Operating expenses | $64.5M | $49.2M | $43.6M | $67.1M | $47.5M | $34.4M | $7.8M | $21.4M | $30.4M | $28.7M | $20.9M | $10.5M | $7.1M | $8.0M |
| Operating income | −$64.5M | −$49.2M | −$43.6M | −$67.1M | −$47.5M | −$34.4M | −$7.8M | −$21.4M | −$30.4M | −$28.7M | −$20.9M | −$7.6M | −$7.1M | −$8.0M |
| EBITDAderived | — | — | — | — | — | — | — | — | — | −$28.6M | −$20.8M | −$7.5M | −$7.1M | −$7.9M |
| Net income | −$57.4M | −$44.6M | −$40.4M | −$66.0M | −$47.3M | −$34.0M | −$7.8M | −$20.7M | −$30.0M | −$28.5M | −$21.4M | −$3.3M | −$7.9M | −$8.0M |
| Basic EPSper diluted share | -$1.34 | -$2.17 | -$3.57 | -$5.86 | -$4.21 | -$4.70 | -$3.04 | -$45.80 | -$2.13 | -$1.72 | -$1.30 | -$3.16 | -$59.66 | -$61.16 |
| Diluted EPSper diluted share | -$1.34 | -$2.17 | -$3.57 | -$5.86 | -$4.21 | -$4.70 | -$3.04 | -$45.80 | -$2.13 | -$1.72 | -$1.30 | -$3.16 | -$59.66 | -$61.16 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 8, 2026Form 4 | Zummo JacquelineChief R&D Officer | SellCommon Stock | 1.1K | $5.40 | $6.1K | 94.8K |
| Apr 1, 2026Form 4 | Zummo JacquelineChief R&D Officer | SellCommon Stock | 22.6K | $5.26 | $118.9K | 96.0K |
| May 14, 2025Form 4/A | Levy Richard SDirector | BuyCommon Stock | 20.0K | $3.19 | $63.8K | 51.0K |
| May 14, 2025Form 4 | Levy Richard SDirector | BuyCommon Stock | 20.0K | $3.19 | $63.8K | 51.0K |
| Mar 26, 2025Form 4 · 10b5-1 | Zummo JacquelineChf Scientific Operations Off | SellCommon Stock | 21.2K | $4.53 | $96.1K | 98.9K |